ALDEYRA THERAPEUTICS, INC. (ALDX) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Current obligations | 9.66M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $9.66M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $24.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $27.81M | $70.04M | $0.00 | (m) | (m) | (m) |
| 2025-09-30 | (m) | $28.48M | $59.34M | $15.96M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $29.53M | $41.24M | $40.68M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $14.29M | $50.35M | $39.71M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $18.60M | $54.53M | $46.62M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $17.15M | $68.12M | $44.62M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $27.59M | $71.03M | $49.30M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $21.68M | $102.49M | $30.55M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $22.26M | (m) | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | (m) | $21.62M | (m) | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | (m) | $15.61M | (m) | $0.00 | (m) | (m) | (m) |
| 2023-03-31 | (m) | $16.01M | (m) | $0.00 | (m) | (m) | (m) |
| 2022-12-31 | (m) | $15.36M | $144.42M | $29.88M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $24.20M | $128.65M | $56.68M | (m) | (m) | (m) |
| 2022-06-30 | (m) | $16.24M | $121.01M | $75.68M | (m) | (m) | (m) |
| 2022-03-31 | (m) | $16.35M | $158.91M | $57.96M | (m) | (m) | (m) |
| 2021-12-31 | (m) | $11.77M | $229.79M | $0.00 | (m) | (m) | (m) |
| 2021-09-30 | (m) | $11.94M | $241.37M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $7.41M | $249.74M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $11.09M | $138.44M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $12.41M | $77.86M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $6.46M | $86.18M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $4.92M | $60.69M | $5.50M | (m) | (m) | (m) |
| 2020-03-31 | (m) | $4.89M | $38.54M | $22.83M | (m) | (m) | (m) |
| 2019-12-31 | (m) | $12.91M | $44.43M | $28.94M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $12.12M | $51.60M | $24.57M | (m) | (m) | (m) |
| 2019-06-30 | (m) | $6.39M | $39.40M | $30.06M | (m) | (m) | (m) |
| 2019-03-31 | (m) | $9.49M | $44.30M | $37.83M | (m) | (m) | (m) |
| 2018-12-31 | (m) | $8.47M | $47.36M | $46.24M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $7.65M | $18.01M | $17.13M | (m) | (m) | (m) |
| 2018-06-30 | (m) | $5.31M | $24.61M | $17.07M | (m) | (m) | (m) |
| 2018-03-31 | (m) | $3.67M | $20.96M | $17.97M | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.35M | $20.02M | $22.92M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.42M | $33.10M | $14.81M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $2.11M | $14.61M | $11.21M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $2.41M | $19.30M | $11.91M | (m) | (m) | (m) |
| 2017-01-01 | (m) | (m) | $12.02M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $2.30M | $12.02M | $12.90M | (m) | (m) | (m) |
| 2016-09-30 | (m) | $2.64M | $14.57M | $14.31M | (m) | (m) | (m) |
| 2016-06-30 | (m) | $2.37M | $17.61M | $14.94M | (m) | (m) | (m) |
| 2016-03-31 | (m) | $1.81M | $10.15M | $12.88M | (m) | (m) | (m) |
| 2016-01-01 | (m) | (m) | $14.65M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.12M | $14.65M | $12.94M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $1.37M | $30.62M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $1.39M | $33.57M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $1.04M | $15.72M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $1.33M | $8.53M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $846.13K | $10.14M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $1.17M | $11.54M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $691.50K | $2.15M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $605.01K | $3.26M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | $2.76M | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | $1.34M | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | $1.68M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $1.22M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |